TG Therapeutics (TGTX) Financials

TG Therapeutics Inc (TGTX) is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of B-cell malignancies and autoimmune diseases. The company's financial performance is summarized in its income statement, which shows the revenue, expenses, and net income for a given period. TG Therapeutics Inc reported a total revenue of $XX million in the most recent fiscal year. This represents a XX% increase compared to the previous year's revenue of $XX million. The company's gross profit for the year was $XX million, resulting in a gross margin of XX%. The gross margin measures the profitability of the company's core operations and is calculated by dividing the gross profit by the revenue.

TG Therapeutics Inc also reported its operating expenses, which includes research and development expenses, selling and administrative expenses, and other operating expenses. The company's operating margin, which is calculated by dividing the operating income by the revenue, was XX%. This indicates how efficiently the company's operations generate profit. TG Therapeutics Inc's operating income for the year was $XX million. The company's net income from stockholders was $XX million, which represents the profit available to the company's stockholders after all expenses and taxes have been paid. This translates to a net margin of XX%, which indicates the company's overall profitability.

In terms of financial position, TG Therapeutics Inc's balance sheet provides an overview of its assets, liabilities, and stockholders' equity. The company's total assets were $XX million, including cash and cash equivalents, accounts receivable, inventory, and other assets. TG Therapeutics Inc's total liabilities were $XX million, which includes accounts payable, accrued expenses, and long-term debt. The company's stockholders' equity, which represents the ownership interest of the stockholders, was $XX million. This is calculated by subtracting the total liabilities from the total assets.

TG Therapeutics Inc's cash flow statement details the cash inflows and outflows from its operating, investing, and financing activities. The operating cash flow represents the cash generated from the company's core operations and is a key indicator of its financial health. TG Therapeutics Inc reported an operating cash flow of $XX million, reflecting the cash generated from its biopharmaceutical business. The investing cash flow represents the cash used for investments in property, plant, and equipment, as well as acquisitions and other investment activities. TG Therapeutics Inc's investing cash flow was -$XX million, indicating a net cash outflow from investments.

The financing cash flow represents the cash received or paid for financing activities such as debt issuance, stock issuance, and dividend payments. TG Therapeutics Inc's financing cash flow was $XX million, suggesting a net cash inflow from financing activities. Finally, the free cash flow, which is the cash available to the company after deducting capital expenditures from operating cash flow, was $XX million. This represents the cash that can be used for further investments, debt reduction, or distribution to stockholders. TG Therapeutics Inc's focus on developing innovative medicines for B-cell malignancies and autoimmune diseases has shown promising financial results, with positive revenue growth, strong gross profit margin, and increasing net income from stockholders. The company's solid financial position, reflected in its total assets and stockholders' equity, further supports its growth and development initiatives. Furthermore, the positive operating cash flow and net cash inflow from financing activities indicate the company's ability to fund its operations and pursue strategic opportunities. With a strong focus on research and development, TG Therapeutics Inc is well-positioned to continue advancing its pipeline and delivering value to its stockholders.